Profusa, Inc. (PFSA) stock
PFSANasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31Also trades as NVACW
$0.45−0.01 (-2.61%)
Close on Nov 13, 2026Market cap $1.13MP/E –Yield –
Profusa EPS
Diluted earnings per share is net income divided by the share count including options and convertible securities.
Profusa's EPS for the twelve months ending Sep 30, 2024 was -$1.73, down 434.8% year over year. For fiscal 2025 it was -$107.01.
Annual eps
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$107.01 | – |
| FY2024 | Dec 31, 2024 | -$357.14 | -111706.3% |
| FY2023 | Dec 31, 2023 | $0.32 | -60.0% |
| FY2022 | Dec 31, 2022 | $0.80 | – |
Quarterly eps
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -$6.23 | – |
| Q2 FY2026 | Jun 30, 2026 | -$151.80 | – |
| Q1 FY2026 | Mar 31, 2026 | -$2.05 | – |
| Q3 FY2025 | Sep 30, 2025 | -$6167.85 | – |
| Q2 FY2025 | Jun 30, 2025 | -$9100.78 | – |
| Q1 FY2025 | Mar 31, 2025 | -$105.09 | -87675.0% |
| Q3 FY2024 | Sep 30, 2024 | -$1.29 | – |
| Q2 FY2024 | Jun 30, 2024 | -$0.19 | -150.0% |
| Q1 FY2024 | Mar 31, 2024 | -$0.37 | -800.0% |
| Q4 FY2023 | Dec 31, 2023 | $0.12 | -52.0% |
| Q3 FY2023 | Sep 30, 2023 | -$0.16 | -220.0% |
| Q2 FY2023 | Jun 30, 2023 | $0.37 | +180.0% |
| Q1 FY2023 | Mar 31, 2023 | $0.05 | -86.7% |
| Q4 FY2022 | Dec 31, 2022 | $0.25 | – |
| Q3 FY2022 | Sep 30, 2022 | $0.13 | – |
| Q2 FY2022 | Jun 30, 2022 | $0.13 | – |
| Q1 FY2022 | Mar 31, 2022 | $0.40 | – |
- Revenue
- Gross Profit
- Operating Income
- Net Income
- EBITDA
- Free Cash Flow
- Operating Cash Flow
- R&D Expenses
- Gross Margin
- Operating Margin
- Profit Margin
- Total Debt
- Cash
- Total Assets
- Shares Outstanding
- Market Cap
- Enterprise Value
- PE Ratio
- Price to Sales Ratio
- Price to Book Ratio
- EV/EBITDA
- Price to Free Cash Flow
- All statistics
See a number that looks wrong?